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Background
There is a risk of developing serious complications of vari-
cella zoster infection (VZI) in juvenile idiopathic arthritis
(JIA) patients receiving disease modifying antirheumatic
drugs (DMARD) including methotrexate and biologic
agents [1,2]. Varicella zoster (VZ) immune status should
therefore be checked in all children before starting such
therapy. Seronegative children mostly receive varicella zos-
ter vaccine (VZV). Vaccination may prevent worried par-
ents and reduce the need for VZ immunoglobulin,
intravenous acyclovir treatment and hospitalization.
Aim
We wanted to investigate the VZ immunity and
response to VV in patients with JIA treated with
DMARD in Northern Norway.
Methods
All patients with a new diagnosis of JIA between 1997-
2010 treated with DMARD in two counties of Northern
Norway were included. The patients were identified using
a prospectively collected study database. We investigated
retrospectively the patients` charts for VZ serological sta-
tus, the response rate to VV, the incidence and treatment
of VZI. If the file did not contain adequate information on
the patients who were non-immune to VZ, we contacted
the patient/parents to complete a telephone survey.
Results
Of the total study group of 150 patients, 71 patients
were treated with DMARD. Before starting treatment 23
of the 71 patients (32%) had negative VZ IgG titer. VZV
was given to 21 of these before starting treatment. VZ
IgG status showed a positive titer in 5 patients after first
VZV, 2 were not checked and 2 had an intermediate
titer. All, except one, of the post-vaccinated VZ IgG
negative patients received a second dose. No serious
complications of the VZV were seen. After some
months 5 of the 15 (33%) seropositive children and 1 in
the intermediate group (50%) developed VZI. One child
developed mild VZI immediately after VZV, the other
children developed VZI 0.5, 1.3, 4.5 and 10,5 years after
VZV. Three of these six children with VZI received acy-
clovir treatment. None of the patients had serious com-
plication or severe illness.
Conclusion
After VZV 33% of the children with positive VZ IgG
titer developed VZI. VZV may give a milder infection in
vaccinated children, as no serious complications or ser-
vere illness was observed in any of the children who
developed VZI.
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